Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 14/20 | 0.66 |
| ▸ | MMP14 | P50281 | 14/20 | 0.66 |
| ▸ | MMP9 | P14780 | 13/20 | 0.66 |
| ▸ | MMP8 | P22894 | 11/20 | 0.66 |
| ▸ | MMP1 | P03956 | 11/20 | 0.66 |
| ▸ | MMP13 | P45452 | 11/20 | 0.66 |
| ▸ | MMP10 | P09238 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | MMP7 | P09237 | 2/20 | 0.54 |
| ▸ | MMP2 | P08253 | 6/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685408 | 0.91 | MMP13 (0.66) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL14993443 | 0.90 | MMP3 (0.52) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL23839848 | 0.88 | MMP14 (0.67) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL14992966 | 0.85 | MMP13 (0.43) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL23828858 | 0.84 | MMP14 (0.70) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL23839851 | 0.82 | MMP14 (0.54) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL14817054 | 0.81 | MMP9 (0.53) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL5908513 | 0.78 | MMP8 (0.50) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL7396792 | 0.78 | MMP3 (0.76) | MMP3MMP14MMP9MMP8MMP1 | |
| SCHEMBL5919374 | 0.77 | MMP13 (0.48) | MMP3MMP14MMP9MMP8MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235818-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750228-B1 | UNCONTROLLED BREAKDOWN OF CONNECTIVE TISSUE BY METALLOPROTEASES IS A FEATURE OF MANY PATHOLOGICAL CONDITIONS | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| EP-1183239-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069821-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235818-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP9, MMP13, MMP2 | MMP3 10/4885MMP14 7/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.